MedPath

Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough

Not Applicable
Completed
Conditions
Cough
Bronchial Hyperreactivity
Interventions
Procedure: bronchial provocation test with mannitol
Registration Number
NCT00916526
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Chronic cough is defined by its persistence beyond 8 weeks. Many conditions can explain the existence of a bronchial inflammation. In the management of chronic cough, the search for bronchial hyperreactivity (HRB) is recommended. The treatment relies primarily on the prescription of inhaled corticosteroids. It has been shown recently that the existence of an HRB with Methacholine (bronchial provocation test used in routine) does predict the effectiveness of inhaled corticosteroid treatment in no more than 50% of cases.

It is now possible to assess the bronchial inflammation by rapid, non-invasive and reproducible tests such that the fraction of exhaled nitric oxide (FeNO) and bronchial provocation test with mannitol. In a retrospective study, it was shown that an increased value of FeNO (cut-off \> 35 ppb) predicts a positive response to treatment with a sensitivity of 90% and a specificity of 80%.

Detailed Description

The purpose of this study is to show that the use of the prospective value of exhaled NO can predict response to treatment with inhaled corticosteroids in adult with chronic cough. In addition we will assess the interest of the prognosis of bronchial provocation test with mannitol in this indication.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Chronic Cough during 2 months
  • Social Security regimen affiliated
  • Consent form signed
Exclusion Criteria
  • Smoking active
  • Treatment with angiotensin converting enzyme inhibitor
  • Clinical signs of obvious gastroesophageal reflux
  • Clinical rhinosinusitis
  • Recent respiratory infection (< 1 month)
  • Corticosteroid Treatment(oral or inhaled) within 2 weeks
  • VEMS < 1 L or < 80% of the theoretical value
  • Existence of an obstructive ventilatory disorder defined as a report (FEV/FVC) < 90% of the theoretical value

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
bronchial provocation test with mannitolbronchial provocation test with mannitolPatients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale. After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests.
Primary Outcome Measures
NameTimeMethod
The intensity of coughing on a 10-cm visual scale6 weeks after treatment with inhaled corticosteroids
Secondary Outcome Measures
NameTimeMethod
Sensitivity, specificity, positive predictive value and negative predictive value of the threshold value of 35 ppb FeNo to the clinical response seen as positive if the EVA reduces cough of at least 2 cm6 weeks after treatment with inhaled corticosteroids
Sensitivity, specificity, positive predictive value and negative predictive value of response to bronchial provocation test with mannitol on the clinical response seen as positive if the EVA reduces cough of at least 2 cm6 weeks after treatment with inhaled corticosteroids
Correlation between the value of FeNo and dose of mannitol causing a fall of 15% of maximum volume expired second (PD15)6 weeks after treatment with inhaled corticosteroids
Score quality of life of the Leicester Cough Questionnaire6 weeks after treatment with inhaled corticosteroids

Trial Locations

Locations (1)

CHU de Saint-Etienne

🇫🇷

Saint-Etienne, France

© Copyright 2025. All Rights Reserved by MedPath